Panacea Index Logo

Command Palette

Search for a command to run...

Effects of early parenteral iron combined erythropoietin in preterm infants: A randomized controlled trial.

Medicine
March 1, 2017
Linxia Qiao et al. (6 authors)
Journal ArticleRandomized Controlled TrialHuman StudyClinical
Study Details

Study Goal

The researchers aimed to evaluate the effect of early parenteral iron supplementation combined with erythropoietin on preventing anemia in preterm infants, including its impact on breastfeeding outcomes.

Results Summary

The study found no significant differences in breastfeeding cases among the groups. Early parenteral iron supplementation combined with erythropoietin improved reticulocyte percentages, reduced total iron binding capacity, and enhanced hemoglobin and mean cell volume levels at 3 months.

Population

Preterm infants

Effective Dosage

Not specified

Duration

2 weeks of life, with follow-up at corrected ages of 1 and 3 months

Interactions

None mentioned

Extracted Claims (38)
InterventionDirectionEndpointPopulationDosageImpactClaim #
iron supplementation
increase
percentages of reticulocyte
preterm infants
2.1±0.4 vs 1.7±0.3
significantly higher
#1
iron supplementation combined erythropoietin
increase
percentages of reticulocyte
preterm infants
2.5±0.3 vs 1.7±0.3
significantly higher
#2
iron supplementation
decrease
total iron binding capacity
preterm infants
36.7±4.6 vs 41.6±5.2
significantly lower
#3
iron supplementation combined erythropoietin
decrease
total iron binding capacity
preterm infants
36.0±4.7 vs 41.6±5.2
significantly lower
#4
iron supplementation
no change
RBC counts
preterm infants
-
no significant differences
#5
iron supplementation combined erythropoietin
no change
RBC counts
preterm infants
-
no significant differences
#6
iron supplementation
no change
hemoglobin levels
preterm infants
-
no significant differences
#7
iron supplementation combined erythropoietin
no change
hemoglobin levels
preterm infants
-
no significant differences
#8
iron supplementation
no change
ferritin levels
preterm infants
-
no significant differences
#9
iron supplementation combined erythropoietin
no change
ferritin levels
preterm infants
-
no significant differences
#10
iron supplementation
no change
malondialdehyde levels
preterm infants
-
no significant differences
#11
iron supplementation combined erythropoietin
no change
malondialdehyde levels
preterm infants
-
no significant differences
#12
iron supplementation
no change
superoxide dismutase levels
preterm infants
-
no significant differences
#13
iron supplementation combined erythropoietin
no change
superoxide dismutase levels
preterm infants
-
no significant differences
#14
iron supplementation
no change
RBC
preterm infants
-
did not differ
#15
iron supplementation combined erythropoietin
no change
RBC
preterm infants
-
did not differ
#16
iron supplementation
no change
Hb
preterm infants
-
did not differ
#17
iron supplementation combined erythropoietin
no change
Hb
preterm infants
-
did not differ
#18
iron supplementation
no change
MCV
preterm infants
-
did not differ
#19
iron supplementation combined erythropoietin
no change
MCV
preterm infants
-
did not differ
#20
iron supplementation
no change
body weight
preterm infants
-
did not differ
#21
iron supplementation combined erythropoietin
no change
body weight
preterm infants
-
did not differ
#22
iron supplementation
no change
body length
preterm infants
-
did not differ
#23
iron supplementation combined erythropoietin
no change
body length
preterm infants
-
did not differ
#24
iron supplementation
no change
head circumference
preterm infants
-
did not differ
#25
iron supplementation combined erythropoietin
no change
head circumference
preterm infants
-
did not differ
#26
iron supplementation
increase
Hb levels
preterm infants
123.7±31.6 vs 114.3±21.3
improved
#27
iron supplementation combined erythropoietin
increase
Hb levels
preterm infants
125.1±21.2 vs 114.3±21.3
improved
#28
iron supplementation
increase
MCV levels
preterm infants
78.3±4.7 vs 74.1±3.5
improved
#29
iron supplementation combined erythropoietin
increase
MCV levels
preterm infants
79.1±5.2 vs 74.1±3.5
improved
#30
iron supplementation
no change
RBC
preterm infants
-
were not different
#31
iron supplementation combined erythropoietin
no change
RBC
preterm infants
-
were not different
#32
iron supplementation
no change
body weight
preterm infants
-
were not different
#33
iron supplementation combined erythropoietin
no change
body weight
preterm infants
-
were not different
#34
iron supplementation
no change
body length
preterm infants
-
were not different
#35
iron supplementation combined erythropoietin
no change
body length
preterm infants
-
were not different
#36
iron supplementation
no change
head circumference
preterm infants
-
were not different
#37
iron supplementation combined erythropoietin
no change
head circumference
preterm infants
-
were not different
#38
Abstract

BACKGROUD: The aim of the study was to evaluate the effect of early parenteral iron supplementation combined erythropoietin for prevention of anemia in preterm infants. METHODS: In total, 96 preterm infants were randomly assigned to 3 groups: a control group receiving standard parenteral nutrition (group 1: n = 31), an iron-supplemented group (group 2: IS, n = 33), and an iron-supplemented combined erythropoietin group (group 3: IS+EPO, n = 32). The primary objective was to assess hemoglobin (Hb) levels. The secondary objectives included assessment of red blood cell counts (RBC), mean cell volume (MCV), serum iron, ferritin, percentages of reticulocyte (RET), total iron binding capacity (TIBC) and oxidative stress, which was assessed by measuring plasma levels of malondialdehyde and superoxide dismutase at baseline and at 2 weeks. The blood routine indices including Hb, RBC, MCV, and percentages of RET were measured at corrected age of 1 and 3 months. RESULTS: At 2 weeks of life, the percentages of reticulocyte in group 2 and group 3 were significantly higher than those in group 1 (2.1±0.4, 2.5±0.3, and 1.7±0.3, respectively, P < 0.001, P<0.001), whereas TIBC were significantly lower than those in group 1 (36.7±4.6, 36.0±4.7, and 41.6 ± 5.2 respectively, P = 0.011, P = 0.006). There were no significant differences in RBC counts, the levels of hemoglobin, ferritin, malondialdehyde, and superoxide dismutase among the 3 groups at 2weeks of life. RBC, Hb, MCV, body weight, body length, and head circumference at a corrected age of 1 month did not differ among 3 groups. At corrected age of 3months, more infants in the control group had abnormal Hb and MCV levels (Hb levels: 114.3 ± 21.3, 123.7 ± 31.6, and 125.1 ± 21.2, P = 0.021, P = 0.034, respectively; MCV: 74.1 ± 3.5, 78.3 ± 4.7 and 79.1 ± 5.2, P = 0.017, P = 0.012, respectively), whereas cases of oral iron, cases of breastfeeding, RBC, body weight, body length, and head circumference were not different among 3 groups. CONCLUSION: Early parenteral iron supplementation combined erythropoietin in preterm infants improved the percentages of reticulocyte, decreased total iron binding capacity, and improved the Hb and MCV levels at 3 months of age. Early parenteral iron supplementations with EPO were beneficial for the preterm infants.

Medical Subject Headings (MeSH)
AnemiaErythropoietinFemaleHumansInfant, NewbornInfant, PrematureIronMale
Study Links
Quality Scores
SafetyNot Assessed
Efficacy75/10
Quality85/10
Citation Metrics
Total Citations11
Citations/Year1.4
Relative Citation Ratio0.72
NIH Percentile38.5%
Research Impact Scores
APT Score0.75
Weight Score1.98
Normalized Score0.67
Related Supplements